How to buy Hikma Pharmaceuticals (HIK) shares

Learn how to easily invest in Hikma Pharmaceuticals shares.

Hikma Pharmaceuticals PLC (HIK) is a leading drug manufacturers-specialty and generic business based in the UK. It opened the day at 2238p after a previous close of 2241p. During the day the price has varied from a low of 2202p to a high of 2243p. The latest price was 2213p (25 minute delay). Hikma Pharmaceuticals is listed on the London Stock Exchange (LSE) and employs 8,600 staff. All prices are listed in pence sterling.

How to buy shares in Hikma Pharmaceuticals

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: HIK in this case.
  5. Research Hikma Pharmaceuticals shares. The platform should provide the latest information available.
  6. Buy your Hikma Pharmaceuticals shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Hikma Pharmaceuticals's share price?

Since the stock market crash that started in February 2020, Hikma Pharmaceuticals's share price has had significant positive movement.

Its last market close was 2018p, which is 4.48% up on its pre-crash value of 1927.5p and 26.44% up on the lowest point reached during the March 2020 crash when the shares fell as low as 1596p.

If you had bought £1,000 worth of Hikma Pharmaceuticals shares at the start of February 2020, those shares would have been worth £929.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,102.03.

Hikma Pharmaceuticals share price (LSE:HIK)

Use our graph to track the performance of HIK stocks over time.

Hikma Pharmaceuticals shares at a glance

Information last updated 2021-12-10.
Open2238p
High2243p
Low2202p
Close2213p
Previous close2241p
Change-28p
Change %-1.2494%
Volume410,616
Information last updated 2022-01-17.
52-week range2044p - 2702.8119p
50-day moving average2234.64p
200-day moving average2407.525p
Wall St. target price27.62p
PE ratio14.1593
Dividend yield52p (1.83%)
Earnings per share (TTM)146.9p
Promoted
eToro Free Stocks

Invest in Hikma Pharmaceuticals shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 20x Hikma Pharmaceuticals shares with popular platforms

Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £0.00
£442.60 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.81
£444.41 total
Capital at risk
IG Share Dealing logo £0 £250 £8.00
£450.60 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £11.95
£454.55 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £7.99
£450.59 total
Capital at risk
Fineco logo £0 No minimum £0.00
£442.60 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £9.50
£452.10 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Hikma Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Hikma Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Hikma Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Hikma Pharmaceuticals shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

PEG ratio

Hikma Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3791. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hikma Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

EBITDA

Hikma Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £726 million.

The EBITDA is a measure of a Hikma Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Financials

Revenue TTM £2.4 billion
Operating margin TTM 24.7%
Gross profit TTM £1.2 billion
Return on assets TTM 9.19%
Return on equity TTM 22.17%
Profit margin 19.26%
Book value 9.895p
Market capitalisation £4.8 billion

TTM: trailing 12 months

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hikma Pharmaceuticals.

Total ESG risk score

Hikma Pharmaceuticals's total ESG risk: 30.38

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hikma Pharmaceuticals's overall score of 30.38 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Hikma Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Environmental score

Hikma Pharmaceuticals's environmental score: 0.84/100

Social score

Hikma Pharmaceuticals's social score: 19.63/100

Governance score

Hikma Pharmaceuticals's governance score: 10.6/100

Controversy score

Hikma Pharmaceuticals's controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Hikma Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Hikma Pharmaceuticals has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Hikma Pharmaceuticals PLC was last rated for ESG on: 2019-01-01.

Total ESG score 30.38
Total ESG percentile 69.56
Environmental score 0.84
Social score 19.63
Governance score 10.6
Level of controversy 1

Hikma Pharmaceuticals share dividends

1.8%

Dividend yield: 1.83% of stock value

1.8%

Forward annual dividend yield: 1.83% of stock value

24.9%

Dividend payout ratio: 24.89% of net profits

Hikma Pharmaceuticals has recently paid out dividends equivalent to 1.83% of its share value annually.

Hikma Pharmaceuticals has paid out, on average, around 24.89% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.83% return on their shares, in the form of dividend payments. In Hikma Pharmaceuticals's case, that would currently equate to about 52p per share.

While Hikma Pharmaceuticals's payout ratio might seem low, this can signify that the company is investing more in its future growth.

The latest dividend was paid out to all shareholders who bought their shares by 19 August 2021 (the "ex-dividend date").

Have Hikma Pharmaceuticals's shares ever split?

Hikma Pharmaceuticals's shares were split on 4 September 2013.

Share price volatility

Over the last 12 months, Hikma Pharmaceuticals's shares have ranged in value from as little as 2044p up to 2702.8119p. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Hikma Pharmaceuticals's is -0.112. This would suggest that Hikma Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Hikma Pharmaceuticals has bucked the trend.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site